The Brown University Child and Adolescent Psychopharmacology Update This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Untreated maternal depression increases risk for preterm birth: Meta ‐analysis
Does maternal depression cause adverse effects on neonates, or do the antidepressants given to pregnant women with depression cause these effects? One meta‐analysis has attempted to answer this question, and found that untreated depression itself raised the risks of adverse effects to newborns, although the risks were much higher in studies in which authors had conflicts of interest — in other words, were supported by pharmaceutical companies making the antidepressants. But the bottom line is that untreated depression, on its own, does lead to risks to the neonate, and of course also has adverse effects for the mother....
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 30, 2016 Category: Psychiatry Tags: Maternal Depression Source Type: research

Untreated maternal depression increases risk for preterm birth: Meta‐analysis
Does maternal depression cause adverse effects on neonates, or do the antidepressants given to pregnant women with depression cause these effects? One meta‐analysis has attempted to answer this question, and found that untreated depression itself raised the risks of adverse effects to newborns, although the risks were much higher in studies in which authors had conflicts of interest — in other words, were supported by pharmaceutical companies making the antidepressants. But the bottom line is that untreated depression, on its own, does lead to risks to the neonate, and of course also has adverse effects for the mother....
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 28, 2016 Category: Psychiatry Tags: Maternal Depression Source Type: research

6 ‐month buprenorphine implant approved
In May, the Food and Drug Administration approved Probuphine, the first buprenorphine implant for treatment of opioid dependence. “The safety and effectiveness of Probuphine have not been established in children or adolescents < 16 years of age,” according to the labeling. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Long ‐delayed mental health reform bill passes unanimously out of committee
Noting that much more work still lies ahead, House Energy and Commerce Committee members, by a unanimous vote of 53–0 on June 15, have finally advanced mental health reform legislation that eliminates many prior controversial provisions, including those involving the Health Insurance Portability and Accountability Act (HIPAA) and the Institutions for Mental Diseases (IMD) exclusion. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: News Source Type: research

Marijuana use disorders and conduct problems declined among teens from 2002 –2013
Researchers looked at trends in the past‐year prevalence of marijuana use disorders (using DSM‐IV criteria) among adolescents, searching for explanations. They found a significant decline — 24% — from the years 2002 to 2013, and the main explanation they suggested for this was a decline in conduct disorders. The resilience factors preventing marijuana use disorders may be the same as those preventing conduct problems, the researchers suggested. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

6‐month buprenorphine implant approved
In May, the Food and Drug Administration approved Probuphine, the first buprenorphine implant for treatment of opioid dependence. “The safety and effectiveness of Probuphine have not been established in children or adolescents < 16 years of age,” according to the labeling. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
Chart review finds atomoxetine safe and effective for ADHD symptoms and social withdrawal of ASD/ID 1 in 6 children with ASD prescribed antipsychotics Anxiety‐BD link found (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: Research Roundup Source Type: research

Long‐delayed mental health reform bill passes unanimously out of committee
Noting that much more work still lies ahead, House Energy and Commerce Committee members, by a unanimous vote of 53–0 on June 15, have finally advanced mental health reform legislation that eliminates many prior controversial provisions, including those involving the Health Insurance Portability and Accountability Act (HIPAA) and the Institutions for Mental Diseases (IMD) exclusion. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: News Source Type: research

Marijuana use disorders and conduct problems declined among teens from 2002–2013
Researchers looked at trends in the past‐year prevalence of marijuana use disorders (using DSM‐IV criteria) among adolescents, searching for explanations. They found a significant decline — 24% — from the years 2002 to 2013, and the main explanation they suggested for this was a decline in conduct disorders. The resilience factors preventing marijuana use disorders may be the same as those preventing conduct problems, the researchers suggested. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Fluoxetine is only antidepressant with better results than placebo in young people
Whether antidepressants work for children and adolescents is controversial; so is the possibility that they may cause or increase suicidality. Researchers compared various medications and placebo, via meta‐analysis. They found that only fluoxetine was more effective at reducing depressive symptoms than placebo, and also that it was better tolerated than the other medications, with fewer discontinuations due to adverse effects. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - June 27, 2016 Category: Psychiatry Tags: Depression Source Type: research

Antidepressant medication shows neural changes in fMRI in teens in small study
If researchers knew what neural changes occur in adolescents who respond to antidepressant medication, they might be able to better understand the mechanisms of depression and treatment, and also be able to use these changes as biomarkers in future studies. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - May 26, 2016 Category: Psychiatry Tags: Depression Source Type: research

FDA warns about rare but serious skin reactions to olanzapine
The Food and Drug Administration (FDA) last month warned that olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. The FDA is adding a new warning to the drug labels for all olanzapine‐containing products that describes this severe condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - May 25, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
Joint Commission standards on eating disorders stress safety Storytelling used as counseling technique for immigrant youth Executive control problems, not sensation‐seeking, most likely to lead teens to regular drug use NIDA reports on loperamide misuse (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - May 25, 2016 Category: Psychiatry Tags: Research Roundup Source Type: research

Researchers study lobeline analogs to treat methamphetamine addiction
Lobeline, a compound that was under investigation for treatment of methamphetamine, didn't work — because it tasted so bad that volunteers resisted taking it. But Linda Dwoskin, Ph.D., of the University of Kentucky College of Pharmacy, who had been working with the drug for 10 years and was encouraged by the fact that it had no adverse effects on humans and did decrease the effects of methamphetamines in lab animals, didn't give up on finding an effective treatment. “Lobeline's failure was a blow,” said Dwoskin in an April report from the National Institute on Drug Abuse. “But I was still very invigorated by the id...
Source: The Brown University Child and Adolescent Psychopharmacology Update - May 25, 2016 Category: Psychiatry Tags: News Source Type: research

Antibiotic plus risperidone may improve irritability and hyperactivity in autism
Autism has no pharmaceutical treatment; however, risperidone is used in managing irritability associated with the disorder. Building on evidence that autism may be related to inflammation, researchers looked at the minocycline, a tetracycline antibiotic, in combination with risperidone in treating children with autism. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - May 25, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research